The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study.
 
Abirami Sivapiragasam
Consulting or Advisory Role - Immunomedics; Pfizer; Puma Biotechnology
 
Ryan Christopher Denley
Stock and Other Ownership Interests - Abbvie (I); Amgen (I)
 
Adam Brufsky
Consulting or Advisory Role - Abbvie; Agendia; Bayer; bioTheranostics; Coherus Biosciences; Coherus Biosciences; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; General Electric; Gilead Sciences; Immunomedics; Lilly; Merck; Michael J. Hennessy Associates; Myriad Pharmaceuticals; Novartis; Onc Live; Pfizer; Puma Biotechnology; Seagen; Tyme
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer
 
Esther Hoogland Rehmus
No Relationships to Disclose
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; GRAIL; Ipsen; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Jennifer A. Crozier
Consulting or Advisory Role - Puma Biotechnology
Research Funding - Agendia (Inst); CytomX Therapeutics (Inst); Merck (Inst); Roche (Inst); Seagen (Inst)
 
Sami Diab
Stock and Other Ownership Interests - Beam; Bluebird Bio; Conatus; Editas Medicine; Fate Therapeutics; Gilead Sciences; Immunogen; Immunomedics; Novocure; Pfizer; Viking Medical
Honoraria - Agendia; AstraZeneca; Genomic Health; Lilly; Myriad Genetics; Novartis; Pfizer
Consulting or Advisory Role - Agendia; Genentech; Genomic Health; Lilly; Myriad Genetics; Novartis; Pfizer; Puma Biotechnology
Speakers' Bureau - Agendia; Genentech; Genomic Health; Lilly; Novartis; Pfizer; Puma Biotechnology
Research Funding - Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genentech; Lilly; Novartis; Pfizer
 
Julie Barone
No Relationships to Disclose
 
Jill Yeager
No Relationships to Disclose
 
Priya Menon
No Relationships to Disclose
 
Midas M. Kuilman
No Relationships to Disclose
 
Lavanya Samraj
No Relationships to Disclose
 
Lisa Eileen Blumencranz
Employment - Agendia
 
M. William Audeh
Employment - Agendia
Leadership - Agendia
Stock and Other Ownership Interests - Agendia
Consulting or Advisory Role - Celanese; Private Health
Research Funding - Agendia
Travel, Accommodations, Expenses - Agendia